Immix Biopharma — $9m private placement to support operations
Immix Biopharma has released a financing and business update, reinforcing its focus on advancing the development of lead CAR-T candidate NXC-201....
541 Views
Immix Biopharma — Fleshing out the CAR-T strategy
Immix has published its Q225 results, reflecting a productive period for NXC-201. The US-based NEXICART-2 trial in relapsed/refractory amyloid...
263 Views
Immix Biopharma — ASCO/KOL event reaffirms NXC-201’s potential
Following Immix’s update at the 61st annual American Society of Clinical Oncology conference (ASCO 2025), the company hosted a key opinion leader...
631 Views
Immix Biopharma — Positive newsflow continues for NEXICART-2
Immix Biopharma has announced a positive clinical update for the US-based Phase I/II NEXICART-2 trial, investigating lead CAR-T candidate NXC-201...
329 Views
Immix Biopharma — Steady progress in Q125
Immix Biopharma’s Q125 results reflect steady progress for NXC-201, its lead CAR-T candidate in clinical development to address amyloid light chain...
309 Views